Enovis (NYSE:ENOV – Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $555.14 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Enovis Price Performance
Shares of NYSE:ENOV opened at $42.77 on Monday. Enovis has a twelve month low of $38.27 and a twelve month high of $65.03. The company’s 50 day moving average is $45.08 and its 200 day moving average is $44.38. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.43 billion, a PE ratio of -19.53 and a beta of 1.94.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th.
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Articles
- Five stocks we like better than Enovis
- Insider Trading – What You Need to Know
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Manufacturing Stocks Investing
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- How to Start Investing in Real Estate
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
